Lysodren Related Published Studies
Well-designed clinical trials related to Lysodren (Mitotane)
Effect of mitotane on pituitary corticotrophs in clinically normal dogs. [2006.08]
Well-designed clinical trials possibly related to Lysodren (Mitotane)
Adrenocortical carcinoma -- improving patient care by establishing new structures. [2006.02]
Other research related to Lysodren (Mitotane)
[Mitotane as possible cause of acute intermittent porphyria]. [2011.09.12]
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. [2011.06]
High (18)F-FDG uptake by the remaining adrenal gland four months after surgery and initiation of mitotane treatment in two patients with adrenocortical carcinoma. [2011.05]
Mitotane has a strong and a durable inducing effect on CYP3A4 activity. [2011.04]
A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. [2011.03]
Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure. [2011]
Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer. [2010.09]
Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. [2010.08.16]
Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. [2010.06]
Development of microemulsion of mitotane for improvement of oral bioavailability. [2010.04]
Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. [2010.03]
The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. [2010.02.18]
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. [2010.01]
[Mitotane in the treatment of adrenal carcinoma]. [2010]
Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. [2009.09.20]
Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy. [2009.06]
Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. [2008.12]
Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism. [2007.12.15]
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. [2007.12]
Adjuvant mitotane treatment for adrenocortical carcinoma. [2007.06.07]
Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane. [2007.02]
Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. [2006.08]
Acute hepatopathy associated with mitotane administration in a dog. [2006.07]
A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients. [2006.06.06]
Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane. [2006.06]
[Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma.] [2006]
A case of adrenal gland dependent hyperadrenocorticism with mitotane therapy in a Yorkshire terrier dog. [2005.12]
A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. [2005.11]
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. [2005.09]
Mitotane for adrenocortical carcinoma treatment. [2005.04]
A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex. [2005.01]
Other possibly related research studies
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. [2006.11]
Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. [2006.08]
Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. [2006.07]
[A long term survival of the patient treated due to advanced adrenocortical carcinoma] [2005.05]
Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. [2006.01]
Adrenocortical carcinoma. [2006.01]
Corticosterone- and aldosterone-secreting adrenocortical tumor in a dog. [2005.05.15]
Clinical features and immunoexpression of p53, MIB-1 and proliferating cell nuclear antigen in adrenal neoplasms. [2005.06]
[Practical use of o,p'DDD in adrenocortical carcinoma] [2005.03]
Biology, clinical characteristics, and management of adrenocortical tumors in children. [2005.09]
[Recurrent operations on the adrenal glands] [2005.03]
[Systemic therapy of malignant adrenal tumors] [2006.05]
Clinical review: Adrenocortical carcinoma: clinical update. [2006.06]
[Treatment of childhood adrenocortical tumor] [2005.10]
[Effects of drugs on the adrenal cortex and its tumors] [2006.02]
Adrenocortical carcinoma. [2007.02]
Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. [2007.03.01]
Pharmacological therapy of Cushing's syndrome: drugs and indications. [2007.05]
Hyperadrenocorticism: treating dogs. [2007.03]
The unique case of adrenocortical malignant and functioning oncocytic tumour. [2007.06]
Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up. [2007.07]
Hyperadrenocorticism: treating dogs. [2007.03]
Medical management of Cushing disease. [2007]
Hyperadrenocorticism: treating dogs. [2007.03]
[Medical treatment for Cushing's syndrome] [2008.01]
A young woman with a severe bilateral pneumonia as the presenting sign of an adrenal carcinoma. [2008.03]
[Management of hypercortisolism] [2008.04]
Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture. [2008.05]
Adjunctive treatment of adrenocortical carcinoma. [2008.06]
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. [2008.06]
Emerging drugs for adrenocortical carcinoma. [2008.09]
[Adrenocortical carcinoma] [2008.06]
Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. [2008.07]
Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review. [2008.08]
Bilateral primary adrenal non-Hodgkin's lymphoma and primary adrenocortical carcinoma--review of the literature preoperative differentiation of adrenal tumors. [2008.08]
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. [2008.07]
Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma. [2008.04]
Pharmacological management of Cushing's syndrome: an update. [2007.11]
Management of adrenocortical carcinoma. [2009.07]
[The medical management of Cushing's syndrome] [2009.04]
Clinical management of adrenocortical carcinoma. [2009.04]
Interindividual differences in o,p'-DDD enantiomer kinetics examined in Gottingen minipigs. [2009.06]
Adrenocortical cancer treatment. [2009.01]
Metastatic adrenocortical carcinoma treated with sunitinib: a case report. [2009.03]
Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. [2008]
A patient with ectopic cortisol production derived from malignant testicular masses. [2008.12]
Successful treatment of adrenocortical carcinoma with pulmonary metastasis in a child: report of a case. [2008]
[Adrenocortical carcinoma. Diagnostic work-up and treatment] [2008.02]
Medical therapy of Cushing's disease: where are we now? [2010]
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. [2010.04.21]
Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center. [2010.02]
Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. [2010.05]
Drugs in the medical treatment of Cushing's syndrome. [2009.12]
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. [2010.02]
Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. [2010.02.01]
Adrenocortical cancer. [2009.10]
Medical management of adrenal disease: a narrative review. [2009.07]
Pneumothorax secondary to pulmonary thromboembolism in a dog. [2009.02]
How is adrenocortical cancer being managed in the UK? [2009.09]
ADH-1 in the Treatment of Metastatic Adrenocortical Carcinoma - Case Report. [2011.11]
Metronomic Therapy Concepts in the Management of Adrenocortical Carcinoma. [2011.10.05]
Contemporary management of adrenocortical carcinoma. [2011.11]
Surgical resection of a virilizing adrenal mass with extensive tumor thrombus. [2011.06]
Thyroid effects and anticancer treatment. [2011.06]
[Management of adrenocortical carcinomas in children]. [2011.05]
Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. [2011.05]
Current and emerging therapies for advanced adrenocortical carcinoma. [2011]
Androgen- and estrogen-secreting adrenal cancers. [2010.12]
|
